CF
TERN

Crosspoint Financial’s Terns Pharmaceuticals TERN Stock Holding History

Crosspoint Financial’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-12,054
Closed -$105K – 10
2023
Q2 		$105K Hold
12,054
– – 1.07% 8
2023
Q1 		$143K Sell
12,054
-3,000
-20% -$28.7K 1.54% 8
2022
Q4 		$153K Buy
+15,054
New +$100K 1.69% 8

Other funds holding TERN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Crosspoint Financial's TERN Position: Q3 2023 in Review

Crosspoint Financial sold out of Terns Pharmaceuticals (TERN) in Q3 2023, closing a stake of 12,054 shares — an estimated $105K sold.

Crosspoint Financial first reported a position in TERN in Q4 2022 and held it in 3 quarters. The position peaked at $153K in Q4 2022. 93 funds tracked by Wall St. Rank hold TERN as of Q3 2023.

  • Crosspoint Financial reported no remaining Terns Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Crosspoint Financial sold 12,054 Terns Pharmaceuticals shares in Q3 2023, an estimated $105K.
  • Crosspoint Financial first reported a position in Terns Pharmaceuticals in Q4 2022 and held it in 3 quarters.
  • Crosspoint Financial's Terns Pharmaceuticals position peaked at $153K in Q4 2022.
  • 93 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q3 2023.

Based on Crosspoint Financial's 13F filing for Q3 2023, filed 14 Nov 2023.